Redeye regards BrightBid’s Q2 as a mixed-bag quarter, where the substantial cost cuts are the positive highlight while the soft q/q cARR growth is the weak point. Although we have lowered our Base Case somewhat, it still constitutes a significant upside potential. Given that BrightBid can accelerate growth in line with our forecasts in 2025, it is heading towards profitability fast following the recent cost cuts. In such a scenario, the current 1.2x sales valuation looks appealing.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/